Stocks Health care IBRX
NASDAQ · Health careImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. brought in $182.6M of revenue over the twelve months to September 30, 2026, up 121.2% from a year earlier. It posted a net loss of $1.1B. In fiscal 2025 capital spending exceeded operating cash flow by $308.8M. At September 30, 2026 it held $45.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about ImmunityBio, Inc.
- Net worth
- ImmunityBio, Inc. has a market value (market cap) of $7.1B at the latest share price, and shareholders' equity of -$1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $113.3M (+668.3% year on year), with a net loss of $351.4M. Over the 12 months to September 30, 2026: revenue $182.6M, net loss $1.1B.
- Cash flow
- In fiscal 2025 operations used $304.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- ImmunityBio, Inc.'s next report is expected around January 14, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What ImmunityBio, Inc. does
ImmunityBio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IBRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $113.3M | -$351.4M | -$0.38 | -$308.8M |
| 2024 | $14.7M | -$413.6M | -$0.62 | -$398.1M |
| 2023 | $622K | -$583.2M | -$1.15 | -$397.3M |
| 2022 | $240K | -$416.6M | -$1.04 | -$415.7M |
| 2021 | $934K | -$346.8M | -$0.89 | -$308M |
| 2020 | $605K | -$221.9M | -$0.59 | -$173.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IBRX ranks in Health care
Latest SEC filings
What ImmunityBio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 52% to $48.8M versus the same quarter last year; diluted EPS -$0.18 versus -$0.07.
- November 9, 2026
- November 9, 2026
- October 14, 2026
- August 6, 2026Activist stake changed SCHEDULE 13D/A
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 94% to $51.2M versus the same quarter last year; diluted EPS -$0.22 versus -$0.10.
- August 4, 2026
- July 30, 2026
- June 10, 2026
- May 18, 2026
Insider trades
What the people running ImmunityBio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Simon Barry J.Director | Soldpre-planned (10b5-1) | 25,000 | $268.8K |
| October 2, 2026 | Cohen CherylDirector | Exercised options | 55,979 | $166.8K |
| October 2, 2026 | Cohen CherylDirector | Soldpre-planned (10b5-1) | 81,056 | $851.1K |
| July 2, 2026 | Cohen CherylDirector | Exercised options | 55,979 | $166.8K |
| July 2, 2026 | Cohen CherylDirector | Soldpre-planned (10b5-1) | 131,210 | $1.2M |
| July 1, 2026 | Selecky ChristobelDirector | Exercised options | 35,064 | $104.5K |
| July 1, 2026 | Selecky ChristobelDirector | Exercised options | 124,414 | $372K |
| July 1, 2026 | Selecky ChristobelDirector | Soldpre-planned (10b5-1) | 159,478 | $1.4M |
Who owns IBRX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Patrick Soon-Shiong13D, may seek influence with 5 related filers | 64.8% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 404 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 34,083,262 | +7,736,819 |
| State Street Corp | 21,398,438 | +3,690,335 |
| Vanguard Portfolio Management LLC | 17,863,911 | +1,541,067 |
| Vanguard Capital Management LLC | 15,691,579 | +563,865 |
| D. E. Shaw & Co., Inc. | 11,551,019 | -1,020,578 |
| Two Sigma Investments, LP | 11,097,106 | +6,711,606 |
| Geode Capital Management, LLC | 9,847,896 | +1,815,975 |
| Millennium Management LLC | 5,579,793 | +4,159,549 |
| Northern Trust Corp | 3,565,248 | +1,060,467 |
| Morgan Stanley | 3,432,678 | -586,191 |
| Goldman Sachs Group Inc | 3,234,277 | -2,801 |
| UBS Group AG | 3,195,728 | +250,840 |
| Charles Schwab Investment Management Inc | 2,888,607 | +410,666 |
| Woodline Partners LP | 2,500,189 | -947,157 |
| SEB Asset Management AB | 2,447,150 | 0 |
| Vanguard Fiduciary Trust Co | 2,412,338 | +289,210 |
| Bank of America Corp | 2,184,489 | -263,354 |
| Voloridge Investment Management, LLC | 1,721,902 | -1,205,650 |
| Federated Hermes, Inc. | 1,713,200 | +326,609 |
| Royal Bank of Canada | 1,542,717 | +56,668 |
Insiders
6 insiders reported holding 284,631,243 shares in total, about $1.92B at the last price.
| Holder | Shares |
|---|---|
| Soon-Shiong PatrickSee remarks, Director, 10% owner | 280,776,784251,018,873 held indirectly |
| Simon Barry J.Director | 2,777,788 |
| Adcock RichardCEO & President, Director | 560,344 |
| Sachs David C.Chief Financial Officer | 300,143 |
| Lauer Regan JChief Accounting Officer | 115,875 |
| Cohen CherylDirector | 100,309 |
Questions about IBRX
What does ImmunityBio, Inc. do?
ImmunityBio, Inc. is a company in the Health care sector, listed on NASDAQ as IBRX. Its shares trade on NASDAQ under the ticker IBRX.
What is ImmunityBio, Inc.'s net worth?
ImmunityBio, Inc. has a market value (market cap) of $7.1B at the latest share price, and shareholders' equity of -$1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is ImmunityBio, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $1.1B on revenue of $182.6M.
How much revenue does ImmunityBio, Inc. make?
Over the twelve months to September 30, 2026 ImmunityBio, Inc. reported revenue of $182.6M. That is 121.2% more than a year earlier.
When did ImmunityBio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is ImmunityBio, Inc.'s next earnings report?
ImmunityBio, Inc.'s next report is expected around January 14, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IBRX with
Follow IBRX
Get an email when ImmunityBio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values ImmunityBio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.